David Kessler, MD
Clinical Cardiac Electrophysiology · Austin, TXNPI 1447251178
Payments from drug & device makers
Across 1,639 payments — averaging $72.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$88K
- Pfizer$12K
- Johnson & Johnson$7K
- Medtronic$5K
- Biosense Webster, Inc.$3K
- E.r. Squibb & Sons, L.L.C.$824
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$27,51343%
- Travel & lodging$8,18413%
- Food & beverage$28,82145%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 798 | $87,666 |
| Pfizer | 88 | $12,459 |
| Johnson & Johnson(2 entities) | 64 | $6,562 |
| Medtronic(2 entities) | 388 | $4,845 |
| Biosense Webster, Inc. | 136 | $3,263 |
| E.r. Squibb & Sons, L.L.C. | 56 | $824 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 33 | $684 |
| Sanofi-aventis U.S. LLC | 24 | $481 |
| Boston Scientific | 7 | $377 |
| Impulse Dynamics (USA) Inc. | 3 | $215 |
| BD | 1 | $139 |
| Irhythm Technologies, Inc. | 5 | $128 |
| Cook Medical LLC | 1 | $127 |
| Novartis | 7 | $123 |
| Regeneron Healthcare Solutions, Inc. | 5 | $122 |
| Atricure, Inc. | 4 | $122 |
| EBR Systems, Inc. | 1 | $111 |
| Cardiva Medical, Inc. | 2 | $73 |
| Baxter Healthcare | 2 | $49 |
| Inspire Medical Systems, Inc. | 2 | $48 |
| Cardiofocus, Inc. | 1 | $48 |
| GSK | 2 | $44 |
| Boehringer Ingelheim | 2 | $35 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $33 |
| Davol Inc. | 1 | $29 |
| Innovation Technologies Inc | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| G Medical Diagnostic Services, Inc. | 1 | $15 |
| Convatec Inc. | 1 | $12 |
| Cvrx, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$11,324
- ENSITE PRECISION$9,534
- XARELTO$5,707
- ENSITE$4,215
- AVEIR$2,218
- Arctic Front$1,417
- AMPLATZER AMULET$1,205
- Ensite Cardiac Mapping System$1,053
- ASSURITY$988
- Cardiac Mapping System$877
- Carto 3$670
- GALLANT$624
- Micra$404
- Fortify Assura, Ellipse ICD$343
- OPTIMIZER$338
- BRK EP Transseptal Access$250
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$176
- NUVISION ICE CATHETER$148
- QDOT MICRO Catheter$148
- Assurity Pacemaker$138
How this compares
$118,678 in reported general payments places this provider in the 75th percentile of 233 clinical cardiac electrophysiology providers in Texas.
See all clinical cardiac electrophysiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,375 | $1,480,589 |
| XareltoRivaroxaban | 667 | $795,390 |
| MultaqDronedarone Hcl | 132 | $176,217 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 257 | $57,025 |
| Flecainide Acetate | 883 | $27,235 |
| Dofetilide | 43 | $14,699 |
| EntrestoSacubitril/Valsartan | 16 | $10,749 |
| PradaxaDabigatran Etexilate Mesylate | 39 | $10,429 |
| Propafenone Hcl | 264 | $10,021 |
| Metoprolol Succinate | 271 | $3,889 |
| Amiodarone Hcl | 338 | $3,192 |
| SotalolSotalol Hcl | 134 | $2,456 |
| Potassium Chloride | 124 | $1,842 |
| Furosemide | 201 | $1,030 |
| Metoprolol Tartrate | 117 | $927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12,459 | $1,480,5891,375 claims |
| Johnson & JohnsonXarelto | $6,562 | $795,390667 claims |
| Sanofi-aventis U.S. LLCMultaq | $481 | $176,217132 claims |
| NovartisEntresto | $123 | $10,74916 claims |
| Boehringer IngelheimPradaxa | $35 | $10,42939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 233 clinical cardiac electrophysiology providers in Texas.
Other clinical cardiac electrophysiology in Austin
- Andrea NataleAustin$7.8M
- Rodney HortonAustin$2.5M
- Robert CanbyAustin$1.5M
- Amin Al-AhmadAustin$1.4M
- Jason ZagrodzkyAustin$961K
- Khaled AwadAustin$745K
- Mauricio HongAustin$726K
- David TschoppAustin$407K
- Javier SanchezAustin$199K
- Weeranun BodeAustin$178K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.